Designing Anti-Viral Vaccines that Harness Intrastructural Help from Prior BCG Vaccination
J Cell Immunol. 2023;5(4):97-102. doi: 10.33696/immunology.5.174.ABSTRACTVaccines are among the most effective tools for combatting the impact and spread of infectious diseases. However, the effectiveness of a vaccine can be diminished by vaccine inequality, particularly during severe outbreaks of infectious diseases in resource-poor areas. As seen in many developing countries that lack adequate healthcare infrastructure and economic resources, the acquisition and distribution of potentially life-saving vaccines may be limited, leading to prolonged suffering and increased deaths. To improve vaccine equity, vaccine design m...
Source: Cellular Immunology - November 10, 2023 Category: Allergy & Immunology Authors: Tony W Ng Steven A Porcelli Source Type: research
Designing Anti-Viral Vaccines that Harness Intrastructural Help from Prior BCG Vaccination
J Cell Immunol. 2023;5(4):97-102. doi: 10.33696/immunology.5.174.ABSTRACTVaccines are among the most effective tools for combatting the impact and spread of infectious diseases. However, the effectiveness of a vaccine can be diminished by vaccine inequality, particularly during severe outbreaks of infectious diseases in resource-poor areas. As seen in many developing countries that lack adequate healthcare infrastructure and economic resources, the acquisition and distribution of potentially life-saving vaccines may be limited, leading to prolonged suffering and increased deaths. To improve vaccine equity, vaccine design m...
Source: Cellular Immunology - November 10, 2023 Category: Allergy & Immunology Authors: Tony W Ng Steven A Porcelli Source Type: research
Designing Anti-Viral Vaccines that Harness Intrastructural Help from Prior BCG Vaccination
J Cell Immunol. 2023;5(4):97-102. doi: 10.33696/immunology.5.174.ABSTRACTVaccines are among the most effective tools for combatting the impact and spread of infectious diseases. However, the effectiveness of a vaccine can be diminished by vaccine inequality, particularly during severe outbreaks of infectious diseases in resource-poor areas. As seen in many developing countries that lack adequate healthcare infrastructure and economic resources, the acquisition and distribution of potentially life-saving vaccines may be limited, leading to prolonged suffering and increased deaths. To improve vaccine equity, vaccine design m...
Source: Cellular Immunology - November 10, 2023 Category: Allergy & Immunology Authors: Tony W Ng Steven A Porcelli Source Type: research
Baseline gene signatures of reactogenicity to Ebola vaccination: a machine learning approach across multiple cohorts
In this study, we developed a machine learning approach to integrate prevaccination gene expression data with adverse events that occurred within 14 days post-vaccination.Results and DiscussionWe analyzed the expression of 144 genes across 343 blood samples collected from participants of 4 phase I clinical trial cohorts: Switzerland, USA, Gabon, and Kenya. Our machine learning approach revealed 22 key genes associated with adverse events such as local reactions, fatigue, headache, myalgia, fever, chills, arthralgia, nausea, and arthritis, providing insights into potential biological mechanisms linked to vaccine reactogenic...
Source: Frontiers in Immunology - November 8, 2023 Category: Allergy & Immunology Source Type: research
The inclusion of pregnant women in vaccine clinical trials: An overview of late-stage clinical trials' records between 2018 and 2023
This study can inform future demands for increased inclusion, especially in industry-sponsored trials, as it provides an overview of the current vaccine trials scene.PMID:37903681 | DOI:10.1016/j.vaccine.2023.10.057 (Source: Vaccine)
Source: Vaccine - October 30, 2023 Category: Allergy & Immunology Authors: Maha Salloum Antea Paviotti Hilde Bastiaens Jean-Pierre Van Geertruyden Source Type: research
The inclusion of pregnant women in vaccine clinical trials: An overview of late-stage clinical trials' records between 2018 and 2023
This study can inform future demands for increased inclusion, especially in industry-sponsored trials, as it provides an overview of the current vaccine trials scene.PMID:37903681 | DOI:10.1016/j.vaccine.2023.10.057 (Source: Vaccine)
Source: Vaccine - October 30, 2023 Category: Allergy & Immunology Authors: Maha Salloum Antea Paviotti Hilde Bastiaens Jean-Pierre Van Geertruyden Source Type: research
The inclusion of pregnant women in vaccine clinical trials: An overview of late-stage clinical trials' records between 2018 and 2023
This study can inform future demands for increased inclusion, especially in industry-sponsored trials, as it provides an overview of the current vaccine trials scene.PMID:37903681 | DOI:10.1016/j.vaccine.2023.10.057 (Source: Vaccine)
Source: Vaccine - October 30, 2023 Category: Allergy & Immunology Authors: Maha Salloum Antea Paviotti Hilde Bastiaens Jean-Pierre Van Geertruyden Source Type: research
BSL-4 facility and New virus research in Japan
Uirusu. 2022;72(1):1-6. doi: 10.2222/jsv.72.1.ABSTRACTViral hemorrhagic fevers such as Ebola virus disease, Marburg disease, Lassa fever, and Crimean-Congo hemorrhagic fever are infectious diseases that can cause severe, life-threatening illness. At present, there are only few licensed vaccines and antiviral drugs for these viral hemorrhagic fevers. The viruses which cause these viral hemorrhagic fevers are classified as BSL-4 pathogens and can be handled only in BSL-4 containment laboratories. Therefore, to develop the vaccines and treatments for these diseases, BSL-4 facility is essential. However, the BSL-4 facility ava...
Source: Uirusu. Journal of Virology - October 29, 2023 Category: Virology Authors: Jiro Yasuda Source Type: research
BSL-4 facility and New virus research in Japan
Uirusu. 2022;72(1):1-6. doi: 10.2222/jsv.72.1.ABSTRACTViral hemorrhagic fevers such as Ebola virus disease, Marburg disease, Lassa fever, and Crimean-Congo hemorrhagic fever are infectious diseases that can cause severe, life-threatening illness. At present, there are only few licensed vaccines and antiviral drugs for these viral hemorrhagic fevers. The viruses which cause these viral hemorrhagic fevers are classified as BSL-4 pathogens and can be handled only in BSL-4 containment laboratories. Therefore, to develop the vaccines and treatments for these diseases, BSL-4 facility is essential. However, the BSL-4 facility ava...
Source: Uirusu. Journal of Virology - October 29, 2023 Category: Virology Authors: Jiro Yasuda Source Type: research
BSL-4 facility and New virus research in Japan
Uirusu. 2022;72(1):1-6. doi: 10.2222/jsv.72.1.ABSTRACTViral hemorrhagic fevers such as Ebola virus disease, Marburg disease, Lassa fever, and Crimean-Congo hemorrhagic fever are infectious diseases that can cause severe, life-threatening illness. At present, there are only few licensed vaccines and antiviral drugs for these viral hemorrhagic fevers. The viruses which cause these viral hemorrhagic fevers are classified as BSL-4 pathogens and can be handled only in BSL-4 containment laboratories. Therefore, to develop the vaccines and treatments for these diseases, BSL-4 facility is essential. However, the BSL-4 facility ava...
Source: Uirusu. Journal of Virology - October 29, 2023 Category: Virology Authors: Jiro Yasuda Source Type: research
BSL-4 facility and New virus research in Japan
Uirusu. 2022;72(1):1-6. doi: 10.2222/jsv.72.1.ABSTRACTViral hemorrhagic fevers such as Ebola virus disease, Marburg disease, Lassa fever, and Crimean-Congo hemorrhagic fever are infectious diseases that can cause severe, life-threatening illness. At present, there are only few licensed vaccines and antiviral drugs for these viral hemorrhagic fevers. The viruses which cause these viral hemorrhagic fevers are classified as BSL-4 pathogens and can be handled only in BSL-4 containment laboratories. Therefore, to develop the vaccines and treatments for these diseases, BSL-4 facility is essential. However, the BSL-4 facility ava...
Source: Uirusu. Journal of Virology - October 29, 2023 Category: Virology Authors: Jiro Yasuda Source Type: research
BSL-4 facility and New virus research in Japan
Uirusu. 2022;72(1):1-6. doi: 10.2222/jsv.72.1.ABSTRACTViral hemorrhagic fevers such as Ebola virus disease, Marburg disease, Lassa fever, and Crimean-Congo hemorrhagic fever are infectious diseases that can cause severe, life-threatening illness. At present, there are only few licensed vaccines and antiviral drugs for these viral hemorrhagic fevers. The viruses which cause these viral hemorrhagic fevers are classified as BSL-4 pathogens and can be handled only in BSL-4 containment laboratories. Therefore, to develop the vaccines and treatments for these diseases, BSL-4 facility is essential. However, the BSL-4 facility ava...
Source: Uirusu. Journal of Virology - October 29, 2023 Category: Virology Authors: Jiro Yasuda Source Type: research
BSL-4 facility and New virus research in Japan
Uirusu. 2022;72(1):1-6. doi: 10.2222/jsv.72.1.ABSTRACTViral hemorrhagic fevers such as Ebola virus disease, Marburg disease, Lassa fever, and Crimean-Congo hemorrhagic fever are infectious diseases that can cause severe, life-threatening illness. At present, there are only few licensed vaccines and antiviral drugs for these viral hemorrhagic fevers. The viruses which cause these viral hemorrhagic fevers are classified as BSL-4 pathogens and can be handled only in BSL-4 containment laboratories. Therefore, to develop the vaccines and treatments for these diseases, BSL-4 facility is essential. However, the BSL-4 facility ava...
Source: Uirusu. Journal of Virology - October 29, 2023 Category: Virology Authors: Jiro Yasuda Source Type: research
BSL-4 facility and New virus research in Japan
Uirusu. 2022;72(1):1-6. doi: 10.2222/jsv.72.1.ABSTRACTViral hemorrhagic fevers such as Ebola virus disease, Marburg disease, Lassa fever, and Crimean-Congo hemorrhagic fever are infectious diseases that can cause severe, life-threatening illness. At present, there are only few licensed vaccines and antiviral drugs for these viral hemorrhagic fevers. The viruses which cause these viral hemorrhagic fevers are classified as BSL-4 pathogens and can be handled only in BSL-4 containment laboratories. Therefore, to develop the vaccines and treatments for these diseases, BSL-4 facility is essential. However, the BSL-4 facility ava...
Source: Uirusu. Journal of Virology - October 29, 2023 Category: Virology Authors: Jiro Yasuda Source Type: research
BSL-4 facility and New virus research in Japan
Uirusu. 2022;72(1):1-6. doi: 10.2222/jsv.72.1.ABSTRACTViral hemorrhagic fevers such as Ebola virus disease, Marburg disease, Lassa fever, and Crimean-Congo hemorrhagic fever are infectious diseases that can cause severe, life-threatening illness. At present, there are only few licensed vaccines and antiviral drugs for these viral hemorrhagic fevers. The viruses which cause these viral hemorrhagic fevers are classified as BSL-4 pathogens and can be handled only in BSL-4 containment laboratories. Therefore, to develop the vaccines and treatments for these diseases, BSL-4 facility is essential. However, the BSL-4 facility ava...
Source: Uirusu. Journal of Virology - October 29, 2023 Category: Virology Authors: Jiro Yasuda Source Type: research
